Paving the way to improved cancer therapy
CEO TOLREMO therapeutics
The topic of drug resistance in cancer has been close to my heart for almost 10 years now. The results of my PhD research suggested new ways to prevent resistance development from the very start of a cancer therapy. This was extraordinarily encouraging.
A most rewarding moment was when we realised that our technology had indeed identified a novel modulator of drug resistance in cancer. It was something that people had told us would not be possible – but we did it anyway!
It was something that people had told us would not be possible – but we did it anyway!